Published in Curr Drug Targets on July 01, 2006
Glucocorticosteroids: current and future directions. Br J Pharmacol (2011) 1.85
Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One (2011) 1.58
Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) (2012) 1.54
Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Control Release (2011) 1.36
Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses. Nat Nanotechnol (2010) 1.36
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) (2010) 1.28
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist (2011) 1.20
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal (2009) 1.11
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs (2010) 1.10
Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem (2008) 1.07
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res (2010) 1.04
4-Isoxazolyl-1,4-dihydropyridines exhibit binding at the multidrug-resistance transporter. Bioorg Med Chem (2012) 1.03
Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm (2010) 1.02
Recent advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance markers and the description of drug/receptor interactions. Int J Parasitol Drugs Drug Resist (2014) 1.02
Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal (2011) 0.99
Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev (2011) 0.93
Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochem Pharmacol (2010) 0.92
Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells. Cancer Res (2010) 0.91
Synthetic Utility of Epoxides for Chiral Functionalization of Isoxazoles. Tetrahedron Lett (2008) 0.91
Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract (2009) 0.91
The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer. J Exp Clin Cancer Res (2009) 0.90
Small and Innovative Molecules as New Strategy to Revert MDR. Front Oncol (2014) 0.88
Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. Cancer Invest (2012) 0.88
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis (2015) 0.87
Astragalus polysaccharides can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing mice. World J Gastroenterol (2012) 0.87
Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des Devel Ther (2009) 0.87
Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. PLoS One (2014) 0.86
Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro. BMC Complement Altern Med (2012) 0.85
Vitamin E reverses multidrug resistance in vitro and in vivo. Cancer Lett (2013) 0.84
Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab (2009) 0.83
Efflux pump-mediated resistance in chemotherapy. Ann Med Health Sci Res (2012) 0.83
Where is it and How Does it Get There - Intracellular Localization and Traffic of P-glycoprotein. Front Oncol (2013) 0.83
Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance. Int J Nanomedicine (2015) 0.81
Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination. J Drug Metab Toxicol (2011) 0.80
Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. Drug Metab Dispos (2009) 0.80
Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf. Biomol Ther (Seoul) (2013) 0.80
The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. Antimicrob Agents Chemother (2014) 0.80
Nanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cells. Mol Pharm (2014) 0.80
3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression. Invest New Drugs (2010) 0.79
Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med (2008) 0.79
P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells. Exp Cell Res (2011) 0.79
β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression. Int J Clin Exp Pathol (2015) 0.79
Reversal of multidrug resistance by 5,5'-dimethoxylariciresinol-4-O-β-D-glucoside in doxorubicin-resistant human leukemia K562/DOX. Indian J Pharmacol (2013) 0.78
Reversal of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR by LY980503. World J Gastroenterol (2007) 0.78
Minocycline hydrochloride nanoliposomes inhibit the production of TNF-α in LPS-stimulated macrophages. Int J Nanomedicine (2012) 0.78
Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R). Invest New Drugs (2008) 0.78
Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. Biol Pharm Bull (2009) 0.78
Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306. Mol Pharm (2014) 0.78
Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications. Biochim Biophys Acta (2015) 0.78
A mathematical feasibility argument for the use of aptamers in chemotherapy and imaging. Math Biosci (2009) 0.78
ATP depletion triggers acute myeloid leukemia differentiation through an ATR/Chk1 protein-dependent and p53 protein-independent pathway. J Biol Chem (2012) 0.76
A Novel Submicron Emulsion System Loaded with Doxorubicin Overcome Multi-Drug Resistance in MCF-7/ADR Cells. Indian J Pharm Sci (2015) 0.75
Cytotoxic effects of loperamide hydrochloride on canine cancer cells. J Vet Med Sci (2014) 0.75
From taxuspine x to structurally simplified taxanes with remarkable p-glycoprotein inhibitory activity. ACS Med Chem Lett (2010) 0.75
Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncol Rep (2016) 0.75
Fluorescent probes of the isoxazole-dihydropyridine scaffold: MDR-1 binding and homology model. Bioorg Med Chem Lett (2013) 0.75
2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance. Bioorg Med Chem (2011) 0.75
Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption. Sci Rep (2016) 0.75
Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One (2017) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
Cellular pharmacology of gemcitabine. Ann Oncol (2006) 2.50
Delta-beta-thalassemia is due to a gene deletion. Cell (1976) 2.12
Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun (1993) 1.91
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. J Physiol (1995) 1.88
Globin gene deletion in HPFH, delta (o) beta (o) thalassaemia and Hb Lepore disease. Nature (1979) 1.88
Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. J Med Chem (2000) 1.87
An erythroid specific enhancer upstream to the gene encoding the cell-type specific transcription factor GATA-1. Nucleic Acids Res (1991) 1.76
Antimicrobial prophylaxis in orthopaedic surgery: the role of teicoplanin. J Antimicrob Chemother (1998) 1.62
The deletion in a type of delta 0-beta 0-thalassaemia begins in an inverted AluI repeat. Nature (1982) 1.56
A protein factor binding to an octamer motif in the gamma-globin promoter disappears upon induction of differentiation and hemoglobin synthesis in K562 cells. Nucleic Acids Res (1987) 1.54
Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet (1992) 1.50
The effects of HPFH mutations in the human gamma-globin promoter on binding of ubiquitous and erythroid specific nuclear factors. Nucleic Acids Res (1988) 1.49
Presence of gene for beta globin in homozygous beta0 thalassaemia. Nature (1976) 1.48
An erythroid specific nuclear factor binding to the proximal CACCC box of the beta-globin gene promoter. Nucleic Acids Res (1988) 1.45
A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemia. EMBO J (1984) 1.44
Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem (1991) 1.28
A direct estimate of the number of human gamma-globin genes. Cell (1976) 1.22
Chemistry and mode of action of macrolides. J Antimicrob Chemother (1993) 1.18
A gene controlling fetal hemoglobin expression in adults is not linked to the non-alpha globin cluster. EMBO J (1983) 1.16
Translational control of globin synthesis by haemin in Xenopus oocytes. Nat New Biol (1973) 1.13
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol (2001) 1.12
Sardinian G gamma-HPFH: a T----C substitution in a conserved "octamer" sequence in the G gamma-globin promoter. Blood (1988) 1.12
Adverse effects of macrolide antibacterials. Drug Saf (1993) 1.09
Molecular comparison of delta beta-thalassemia and hereditary persistence of fetal hemoglobin DNAs: evidence of a regulatory area? Proc Natl Acad Sci U S A (1982) 1.02
Direct demonstration of beta-globin mRNA in homozygous Ferrara betaO-thalassaemia patients. Nature (1977) 1.02
Increased erythroid-specific expression of a mutated HPFH gamma-globin promoter requires the erythroid factor NFE-1. Nucleic Acids Res (1989) 1.01
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant (2004) 1.01
Sardinian delta beta zero-thalassemia: a further example of a C to T substitution at position -196 of the A gamma globin gene promoter. Blood (1987) 0.99
Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet (1989) 0.98
Globin chain synthesis in single erythroid bursts from cord blood: studies on gamma leads to beta and G gamma leads to A gamma switches. Proc Natl Acad Sci U S A (1980) 0.97
Immortalization of multipotent growth-factor dependent hemopoietic progenitors from mice transgenic for GATA-1 driven SV40 tsA58 gene. EMBO J (1994) 0.95
Human globin chain separation by isoelectric focusing. J Biochem Biophys Methods (1979) 0.94
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer (2002) 0.94
Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II). Clin Pharmacokinet (1989) 0.93
Regulation of mouse p45 NF-E2 transcription by an erythroid-specific GATA-dependent intronic alternative promoter. J Biol Chem (2000) 0.91
Biosynthesis of Hb in individual fetal liver bursts. gamma-Chain production peaks earlier than beta-chain in the erythropoietic pathway. Exp Cell Res (1980) 0.91
G gamma and A gamma globin chains separation and quantitation by isoelectric focusing. Biochem Biophys Res Commun (1979) 0.90
4-Hydroxynonenal, a product of cellular lipid peroxidation, which modulates c-myc and globin gene expression in K562 erythroleukemic cells. Cancer Res (1992) 0.90
Italian type of deletional hereditary persistence of fetal hemoglobin. Blood (1986) 0.90
Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian Study Group for Antimicrobial Prophylaxis in Orthopedic Surgery. Eur J Clin Microbiol Infect Dis (1999) 0.90
Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells. Cancer Res (1985) 0.88
Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res (1988) 0.88
Human T gamma globin chain is a variant of A gamma chain (A gamma Sardinia). Proc Natl Acad Sci U S A (1979) 0.87
Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anticancer Drugs (1995) 0.87
Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. Cancer Treat Rep (1987) 0.87
DNA sequences regulating human globin gene transcription in nondeletional hereditary persistence of fetal hemoglobin. Hemoglobin (1989) 0.86
Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas. Scand J Gastroenterol (2000) 0.86
Hemoglobin synthesis in individual bursts from normal adult blood: all bursts and subcolonies synthesize G gamma-and A gamma-globin chains. Blood (1980) 0.86
Mutations of the APC gene in human sporadic colorectal cancers. Scand J Gastroenterol (2002) 0.85
Globin RNA sequences in human leukaemic peripheral blood. Nature (1978) 0.85
The beta-globin gene in Sardinian delta beta 0-thalassemia carries a C----T nonsense mutation at codon 39. EMBO J (1984) 0.84
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm). J Inorg Biochem (1997) 0.84
Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Cancer Res (1985) 0.84
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. Cancer Lett (2000) 0.83
Mutations in the A gamma-globin promoter in hereditary persistence of fetal hemoglobin and delta beta zero-thalassemia. Prog Clin Biol Res (1987) 0.83
A frequent A gamma-hereditary persistence of fetal hemoglobin in northern Sardinia: its molecular basis and hematologic phenotype in heterozygotes and compound heterozygotes with beta-thalassemia. Hum Genet (1988) 0.82
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. Dig Liver Dis (2004) 0.81
Transcriptional and post-transcriptional defects in beta0-thalassaemia. Eur J Biochem (1977) 0.81
Preferential induction of fetal versus embryonic globin chains in human leukemic cell lines. Leuk Res (1982) 0.81
Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. Anticancer Drug Des (1994) 0.81
Long-term azithromycin in cystic fibrosis: another possible mechanism of action? J Chemother (2005) 0.81
Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. Anticancer Drug Des (1998) 0.81
Ribosomal subunits from rat liver. Isolation and recombination into active ribosomal particles. Ital J Biochem (1971) 0.80
Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor. Int J Cancer (2000) 0.80
Teicoplanin--its role as systemic therapy of burn infections and as prophylaxis for orthopaedic surgery. Italian Study Groups for Antimicrobial Prophylaxis in Orthopaedic Surgery and Burns. Eur J Surg Suppl (1992) 0.80
Analysis of human embryonic hemoglobins and globins by isoelectric focusing. Haematologica (1983) 0.80
Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res (1998) 0.80
Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer Detect Prev (1991) 0.79
Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Semin Oncol (1983) 0.79
Mapping the gene encoding the human erythroid transcriptional factor NFE1-GF1 to Xp11.23. Hum Genet (1991) 0.79
Bromodeoxyuridine treatment of normal adult erythroid colonies: an in vitro model for reactivation of human fetal globin genes. Blood (1986) 0.78
Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol Res (1994) 0.78
Flow cytometric analysis of DNA ploidy and cell proliferation activity in colorectal carcinoma. Anticancer Res (1996) 0.78
Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells. Biochem Pharmacol (1987) 0.78
Induction of differentiation of HL-60 cells along the monocytic pathway by 5-methyltetrahydrofolate. J Chemother (1989) 0.78
Organization of alpha-globin genes in Hb Hasharon (alpha 47 asp replaced by his) carriers. Blood (1980) 0.78
Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. Cancer Lett (1998) 0.78
A model for hemoglobin F synthesis in adult life: evidence for regulation at the level of erythroblasts. Ann N Y Acad Sci (1985) 0.78
Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study. Anticancer Res (2003) 0.78
Tumorigenic activity of a rearranged c-myc gene from a human T-cell leukemia line. Carcinogenesis (1992) 0.78
Single-dose ceftriaxone versus multi-dose cefotaxime antimicrobial prophylaxis in gynecologic and obstetrical surgery. Preliminary results of a multicenter prospective randomized study. Chemioterapia (1984) 0.78
High Hb F levels in a Sardinian family: a genetic defect intermediate between HPFH Greek type and delta beta-thalassemia? Haematologica (1982) 0.77
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol (2001) 0.77
Expression in hematopoietic cells of GATA-1 transcripts from the alternative "testis" promoter during development and cell differentiation. Biochem Biophys Res Commun (1997) 0.77
Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma. Cancer Invest (1991) 0.77
Modulation of fluoropyrimidine cytotoxicity by methotrexate or 5-methyltetrahydrofolate in human leukemia cells in vitro. Chemioterapia (1984) 0.77
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). Chem Biol Interact (2000) 0.77
Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity. Oncol Res (2000) 0.77
Drug resistance in cancer: an overview of the clinical aspects. J Chemother (1989) 0.77
Biosynthesis of globin chains in fetal liver and adult marrow cultures. Exp Cell Res (1981) 0.77
Tissue penetration and pulmonary disposition of tobramycin. J Chemother (1995) 0.77
Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial. J Int Med Res (1990) 0.77
Altered binding to the gamma-globin promoter of two erythroid specific nuclear proteins in different HPFH syndromes. Prog Clin Biol Res (1989) 0.77
delta beta-Thalassemia and HPFH. Birth Defects Orig Artic Ser (1982) 0.77
Selecting antibacterial agents for the control of surgical infection: mini-review. J Chemother (1998) 0.77
Globin -chain synthesis directed by "supernatant" 10S RNA from rabbit reticulocytes. Nat New Biol (1972) 0.77
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. J Chemother (2008) 0.76
Design and rationale for novel antifolates. NCI Monogr (1987) 0.76
Intra-arterial hepatic chemotherapy with 5-fluorouracil and 5-methyltetrahydrofolate in the treatment of unresectable liver metastases from colorectal cancer. Anticancer Res (1995) 0.76
The Charta of Milan: basic criteria for the appropriate and accurate use of antibiotics: recommendations of the Italian Society of Chemotherapy. J Chemother (2009) 0.76